References
- XuWChenQWangQJWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cellsCell Death Dis2014512e155125476899
- ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
- CatalanoVLabiancaRBerettaGDGattaGde BraudFvan CutsemEGastric cancerCrit Rev Oncol Hematol200971212716419230702
- ChabnerBARobertsTGTimeline: chemotherapy and the war on cancerNat Rev Cancer200551657215630416
- KimBLeeKWKimMJA multicenter randomized Phase II study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after Cisplatin Plus Either S-1 or CapecitabineEur J Cancer2017493706716
- BangYJvan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
- WilkeHMuroKvan CutsemERamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol201415111224123525240821
- ChoKWangXNieSChenZGShinDMTherapeutic nanoparticles for drug delivery in cancerClin Cancer Res20081451310131618316549
- FengS-SZhaoLZhangZChemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivoChem Eng Sci2007622366416648
- WangXYangLChenZGShinDMApplication of nanotechnology in cancer therapy and imagingCA Cancer J Clin20085829711018227410
- YooHSParkTGFolate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugateJ Control Release2004100224725615544872
- BrownKCPeptidic tumor targeting agents: the road from phage display peptide selections to clinical applicationsCurr Pharm Des20101691040105420030617
- AdamsGPWeinerLMMonoclonal antibody therapy of cancerNat Biotechnol20052391147115716151408
- AhlgrenSWållbergHTranTATargeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteineJ Nucl Med200950578178919372467
- BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
- BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
- GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
- RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
- PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
- TopalianSLDrakeCGPardollDMTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurr Opin Immunol201224220721222236695
- DasSSuarezGBeswickEJSierraJCGrahamDYReyesVEExpression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylor infectionJ Immunol200617653000300916493058
- KimJWNamKHAhnSHPrognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancerGastric Cancer2016191425225424150
- QingYLiQRenTUpregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancerDrug Des Devel Ther20159901909
- WuCZhuYJiangJZhaoJZhangXGXuNImmunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significanceActa Histochem20061081192416530813
- HouJYuZXiangRCorrelation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancerExp Mol Pathol201496328429124657498
- GengYWangHLuCExpression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significanceInt J Clin Oncol201520227328124804867
- NishiyamaNKataokaKCurrent state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene deliveryPharmacol Ther2006112363064816815554
- LiRLiXXieLPreparation and evaluation of PEG-PCL nanoparticles for local tetradrine deliveryInt J Pharm2009379115816619524653
- LiuYLiKLiuBFengSSA strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug deliveryBiomaterials201031359145915520864169
- WangYGaoSYeWHYoonHSYangYYCo-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymerNat Mater200651079179616998471
- ZhangDZouZRenWGambogic acid-loaded PEG-PCL nanoparticles act as an effective antitumor agent against gastric cancerPharm Dev Technol2018231334029069711
- JungJParkSJChungHKPolymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancerInt J Radiat Oncol Biol Phys2012841e77e8322795728
- EinzigAINeubergDRemickSCPhase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293Med Oncol199613287939013471
- Thuss-PatiencePCKretzschmarAReppMDocetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II studyJ Clin Oncol200523349450115659494
- SharmaPAllisonJPThe future of immune checkpoint therapyScience20153486230566125838373
- GongWSongQLuXPaclitaxel induced B7-H1 expression in cancer cells via the MAPK pathwayJ Chemother201123529529922005063
- PatelSPKurzrockRPD-L1 expression as a predictive biomarker in Cancer immunotherapyMol Cancer Ther201514484785625695955
- LiangSCLatchmanYEBuhlmannJERegulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responsesEur J Immunol200333102706271614515254
- WangAZLangerRFarokhzadOCNanoparticle delivery of cancer drugsAnnu Rev Med2012636318519821888516
- FriedmanADClaypoolSELiuRThe smart targeting of nanoparticlesCurr Pharm Des201319356315632923470005
- WhiteheadKALangerRAndersonDGKnocking down barriers: advances in siRNA deliveryNat Rev Drug Discov20098212913819180106
- RamakrishnanRAssudaniDNagarajSChemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in miceJ Clin Invest201012041111112420234093
- van der MostRGCurrieAJCleaverALCyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growthPLoS One200949e698219746156
- GalluzziLBuquéAKeppOZitvogelLKroemerGImmunological effects of conventional chemotherapy and targeted anticancer agentsCancer Cell201528669071426678337
- MénardCMartinFApetohLBouyerFGhiringhelliFCancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunityCancer Immunol Immunother200857111579158718369619
- GadgeelSStevensonJLangerCJPembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-CJ Clin Oncol2016suppl 1590169016
- MartinoECMissoGPastinaPImmune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patientsCell Death Discov201621602527752361
- AtzpodienJKirchnerHJonasUInterleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German cooperative renal carcinoma chemoimmunotherapy group (DGCIN)J Clin Oncol20042271188119414981107
- ParraHSTixiLLatteriFCombined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)Cancer200192365065611505411